Daniel S. Lynch has served as chairman of our board of directors since May 2011, when he joined Third Rock Ventures as an entrepreneur-in-residence. Since October 2007, Mr. Lynch has advised and served as executive chair or member of the board of directors for a number of private biopharmaceutical companies, which include Stromedix, Inc. (until its acquisition by Biogen Idec in February 2012), Avila Therapeutics, Inc. (until its acquisition by Celgene Corporation in February 2012), Translate Bio, Inc. (formerly known as RaNA Therapeutics, Inc.), Nimbus Discovery, LLC, Edimer Pharmaceuticals, Ember Therapeutics, Inc., Proclara Biosciences, Inc., and Surface Oncology, Inc. He currently serves on the board of directors of Blueprint Medicines Corporation, and Sesen Bio, Inc., and formerly for BIND Biosciences, Inc. Mr. Lynch joined Third Rock Ventures, L.P., or Third Rock, as an entrepreneur-in-residence in May 2011, and became a Venture Partner in May 2013, and now he is a senior advisor. Previously, Mr. Lynch served as chief executive and chief financial officer of ImClone Systems Corporation, or ImClone. As ImClone’s chief executive officer, he led ImClone through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX (Cetuximab), a novel cancer treatment. As its chief financial officer, Mr. Lynch led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He served on the board of directors and the audit committee of U.S. Oncology, Inc. for five years until December 2010, when it was acquired by McKesson. Mr. Lynch received his B.A. in mathematics from Wesleyan University and his M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.

John O. Agwunobi, M.D., has served as a member of our board of directors since June 2017. Since February 2016, Dr. Agwunobi has served as chief health and nutrition officer at Herbalife Nutrition Institute, responsible for training, education, science strategy and product development. Prior to joining Herbalife, Dr. Agwunobi was an independent consultant, advising a number of privately-held health-related companies, including serving as an advisory board member of Shopko Stores Operating Co., LLC on behalf of the private equity firm Sun Capital Partners. From September 2007 to April 2014, Dr. Agwunobi served as senior vice president and president of health and wellness for Wal-Mart in the United States where he grew the business and provided insight and advice on the company’s health reform position. From December 2005 to September 2007, he served as the assistant secretary of health for the U.S. Department of Health and Human Services, where he was responsible for disease prevention and health promotion. His responsibilities included the oversight of the Centers for Disease Control, National Institute of Health, the U.S. Food and Drug Administration, the office of the U.S. Surgeon General, and numerous other public health offices and programs. Dr. Agwunobi has served on numerous boards, including currently as a director at Magellan Health Inc. and at the U.S. African Development Foundation. Dr. Agwunobi is a licensed physician in Florida, Maryland and Washington, D.C. He received his medical training at the University of Jos and completed his pediatric residency at Howard University. He also holds a Master’s Degree in Public Health from Johns Hopkins University and Master’s in Business Administration from Georgetown University.

Wendy L. Dixon, Ph.D., has served as a member of our board of directors since April 2013. In 2012, Dr. Dixon served as senior advisor at The Monitor Group. Dr. Dixon serves as a member of the board of directors for a number of biopharmaceutical companies, including Alkermes PLC, Incyte Corporation, Eleven Biotherapeutics, Inc. and Voyager Therapeutics, Inc., and formerly for Orexigen Therapeutics Inc., Furiex Pharmaceuticals, Inc., which was sold to Forest Laboratories, LLC as a subsidiary of Allergan in 2014, Ardea Biosciences, Inc., which was sold to AstraZeneca PLC in 2012, and Dentsply International Inc., as well as a private company, Edimer Pharmaceuticals, Inc. Dr. Dixon also served as chief marketing officer and president of Global Marketing for Bristol-Myers Squibb and as a member of the CEO’s Executive Committee from 2001 to 2009. She has had an over 30-year career in the pharmaceutical and biotechnology business, combining a technical background and experience in drug development and regulatory affairs with commercial responsibilities in building and leading organizations and launching and growing more than 20 pharmaceutical products including Tagamet, Fosamax, Singulair, Plavix, Abilify, Reyataz and Baraclude. From 1996 to 2001, she was senior vice president, marketing at Merck and prior to that she held executive management positions at West Pharmaceuticals, Osteotech and Centocor, and various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon received her B.Sc., M.Sc. and Ph.D. from the University of Cambridge (UK).

Nick Leschly has served as our chief bluebird since September 2010. Formerly, Nick was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE. Nick also founded and served as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO) and Synlogic Therapeutics.

Douglas A. Melton, Ph.D., has served as a member of our board of directors since June 2017. Dr. Melton is the Xander University Professor at Harvard University, where he has been a professor for over thirty years. He has served as the co-director of the Harvard Stem Cell Institute since 2004, and also as the co-chair of the Department of Stem Cell and Regenerative Biology since 2007. Since 1994, Dr. Melton has been an investigator of the Howard Hughes Medical Institute. He is a scientific co-founder of Gilead Sciences, Inc., Curis, Inc. and Semma Therapeutics, Inc. Dr. Melton received a B.S. in Biology from the University of Illinois, a B.A. in History and Philosophy of Science at Cambridge University, and received his Ph.D. in molecular biology at Trinity College at Cambridge and the MRC Laboratory of Molecular Biology.

David P. Schenkein, M.D., has served as a member of our board of directors since April 2013. Since August 2009, Dr. Schenkein has served as the chief executive officer of Agios Pharmaceuticals, Inc. From April 2006 to July 2009, Dr. Schenkein served as senior vice president of oncology development of Genentech. Dr. Schenkein is also a director at Agios Pharmaceuticals, Inc., and Denali Therapeutics, and served on the board of directors of Foundation Medicine, Inc. from April 2010 to April 2017. Dr. Schenkein received his B.A. in chemistry from Wesleyan University and his M.D. from Upstate Medical School.

William R. Sellers, M.D. has served as a member of our board since September 2019. Dr. Sellers currently leads a research group focused on translating genomic discoveries into new therapeutics as a Core Institute Member at the Broad Institute of MIT and Harvard, and as a Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. Previously, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for Biomedical Research overseeing scientists, clinicians and clinical staff on sites in Cambridge, East Hanover, Basel and Shanghai from 2005-2016. During his tenure he conceptualized and directed a collaboration with the Broad Institute on the Cancer Cell Line Encyclopedia, the development of the Novartis Primary Derived Xenograft Encyclopedia and large-scale efforts to functionally characterize the cancer genome. Along with Dr. Carl June, he co-chaired the CART research collaboration with the University of Pennsylvania that brought CTL019 to a recent FDA approval.

Dr. Sellers was previously an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute. Together with Matthew Meyerson, he initiated and developed large-scale efforts to re-sequence genes in diverse cancer types, which led to the development of the widely used GISTIC algorithm, the discovery of EGFR mutations in lung adenocarcinoma and the discovery of the oncogenic role of the MITF gene in melanoma. In addition, his work advanced the understanding of the molecular mechanisms of growth regulation of the PTEN tumor suppressor gene.

Dr. Sellers received his B.S. from Georgetown University in 1982 and M.D. from the University of Massachusetts Medical School in 1986. He completed residency training in Internal Medicine at the University of California San Francisco in 1989 and trained in Medical Oncology at the Dana-Farber Cancer Institute. Dr. Sellers is a former member of the National Cancer Advisory Board.

Mark Vachon has served as a member of our board of directors since July 2014. Mr. Vachon served as an executive vice president sales, integration and operations at Change Healthcare Holdings, Inc. from November 2016 to April 2018. For over 30 years, Mr. Vachon held a variety of leadership positions across the General Electric organization, and was a company officer beginning in 1999 and a member of GE’s Corporate Executive Council. Mr. Vachon was president and chief executive officer of GE Healthcare Americas from 2009 and 2010, and prior to that he was president and chief executive officer of Global Diagnostics Imaging, GE Healthcare, between 2006 and 2009. Between 2003 and 2006, Mr. Vachon was executive vice president and chief financial officer of GE Healthcare. Mr. Vachon serves on the board of trustees of Northeastern University and the board of directors of Numotion, and the Charitable Health and Retirement Trust. Mr. Vachon holds a B.S. in Finance from Northeastern University and an M.A. from Boston College.